Designed as a centre for technical development and knowledge sharing, the new facilities offer expanded laboratory capabilities for product innovation, alongside a dedicated learning space for technical seminars, workshops, and collaborative learning. The facilities bring together IMCD teams, customers and suppliers under one roof to collaborate on leading solutions across the pharmaceutical, nutraceutical, and food and beverage markets, accelerating the transformation of ideas into real-world solutions with greater speed and efficiency. The local facilities will benefit from state-of-the-art technical capabilities, connected to experts across the Global lab network via our digital analytics platform.
The Food & Nutrition US Technical Hub features a dedicated Food & Nutrition Application Lab and Bakery Lab designed for the co-creation of trend-driven formulation solutions across bakery, beverage, confectionery, dairy, nutrition, and savoury applications. From concept ideation and prototype development to formulation optimisation, the centre empowers local customers to bring innovative concepts to life and accelerate speed to market with market-ready solutions.
Emilie Pharand, Vice-President Food & Nutrition, North America, IMCD: “Our US Technical Hub is more than a laboratory; it represents an exciting milestone in our commitment to supporting our North American customers and partners. It is a destination for collaboration, creativity, and technical excellence, where market understanding and formulation expertise come together to accelerate ideas from concept to commercialisation. We are excited to welcome customers and partners into this space to co-create what’s next.”
The Pharmaceutical Technical Centre will support the development of patient-friendly solid, semi-solid and liquid formulations for pharmaceuticals and dietary supplements with state-of-the-art equipment and technologies. This includes regulatory advice, practical training and knowledge exchange in the global laboratory network.
Sibu Varghese, Vice President of IMCD Pharmaceuticals US, commented: “By combining IMCD’s global expertise with deep local insight, these new facilities will provide valuable technical resources to help North American customers accelerate product development across a broad range of dosage forms, supported by active pharmaceutical ingredients (API) and formulation expertise.”
Source: chemanager-online.com
Bayer has sold a stake in its newly established contraceptives offshoot to global asset management firm Apollo for €3bn ($3.4bn) – allowing the company to access funds without relinquishing overall control of the business.
Mittal succeeds Peter Bains, who completed his tenure as Managing Director & CEO on 30 June 2026, bringing close to three decades of business leadership experience. He joins Syngene from Biocon Limited, where he most recently served as the Managing Director and Chief Executive Officer.
Evonik is modernizing its active pharmaceutical ingredient production at its Tippecanoe site in Lafayette, Indiana. Over the next five years, the company will invest $100 million in upgrading key equipment used in the manufacture of active pharmaceutical ingredients.
